BACKGROUND: First-generation, E1-deleted (deltaE1) adenovirus vectors currently used in cardiovascular gene therapy trials are limited by tissue inflammation, mainly due to immune responses to viral gene products. Recently, helper-dependent (HD; also referred to as "gutless") adenovirus vectors devoid of all viral coding sequences have been shown to cause low inflammation when injected intravenously or into skeletal muscles. However, HD vectors have not been evaluated in cardiovascular tissues. METHODS AND RESULTS: HD and deltaE1 vectors containing a cytomegalovirus-driven expression cassette for the green fluorescent protein (GFP) gene were administered intramyocardially to adult rats (n = 54). GFP expression was measured by ELISA at varyi...
Neointima formation and vascular remodeling through vascular smooth muscle cell migration and prolif...
Neointima formation and vascular remodelling through vascular smooth muscle cell migration and proli...
AbstractObjective: Because of the relative inaccessibility of the heart for repeated gene therapy, i...
BACKGROUND: First-generation, E1-deleted (deltaE1) adenovirus vectors currently used in cardiovascul...
Abstract. : Background: : First-generation, E1-deleted (ΔE1) adenovirus vectors currently used in ca...
Direct injection of adenovirus (Ad) has been suggested as an efficient method for in vivo gene trans...
Plasmid DNA and adenovirus vectors currently used in cardiovascular gene therapy trials are limited ...
The vascular response to any given combination of gene transfer vector and catheter delivery system ...
Therapeutic angiogenesis induced by gene therapy is a promising approach to treat patients suffering...
AbstractRecombinant cross-packaging of adeno-associated virus (AAV) genome of one serotype into othe...
The utility of adenoviral vectors for arterial gene transfer is limited by the brevity of their expr...
The utility of adenoviral vectors for arterial gene transfer is limited by the brevity of their expr...
AbstractRecombinant cross-packaging of adeno-associated virus (AAV) genome of one serotype into othe...
Neointima formation and vascular remodeling through vascular smooth muscle cell migration and prolif...
Neointima formation and vascular remodeling through vascular smooth muscle cell migration and prolif...
Neointima formation and vascular remodeling through vascular smooth muscle cell migration and prolif...
Neointima formation and vascular remodelling through vascular smooth muscle cell migration and proli...
AbstractObjective: Because of the relative inaccessibility of the heart for repeated gene therapy, i...
BACKGROUND: First-generation, E1-deleted (deltaE1) adenovirus vectors currently used in cardiovascul...
Abstract. : Background: : First-generation, E1-deleted (ΔE1) adenovirus vectors currently used in ca...
Direct injection of adenovirus (Ad) has been suggested as an efficient method for in vivo gene trans...
Plasmid DNA and adenovirus vectors currently used in cardiovascular gene therapy trials are limited ...
The vascular response to any given combination of gene transfer vector and catheter delivery system ...
Therapeutic angiogenesis induced by gene therapy is a promising approach to treat patients suffering...
AbstractRecombinant cross-packaging of adeno-associated virus (AAV) genome of one serotype into othe...
The utility of adenoviral vectors for arterial gene transfer is limited by the brevity of their expr...
The utility of adenoviral vectors for arterial gene transfer is limited by the brevity of their expr...
AbstractRecombinant cross-packaging of adeno-associated virus (AAV) genome of one serotype into othe...
Neointima formation and vascular remodeling through vascular smooth muscle cell migration and prolif...
Neointima formation and vascular remodeling through vascular smooth muscle cell migration and prolif...
Neointima formation and vascular remodeling through vascular smooth muscle cell migration and prolif...
Neointima formation and vascular remodelling through vascular smooth muscle cell migration and proli...
AbstractObjective: Because of the relative inaccessibility of the heart for repeated gene therapy, i...